Erasca, Inc. (ERAS)
15.88
-0.15
(-0.94%)
USD |
NASDAQ |
Sep 11, 16:00
15.88
0.00 (0.00%)
After-Hours: 20:00
Erasca Enterprise Value : 4.739B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 4.739B |
| September 10, 2026 | 4.786B |
| September 09, 2026 | 4.683B |
| September 08, 2026 | 4.864B |
| September 04, 2026 | 4.836B |
| September 03, 2026 | 4.858B |
| September 02, 2026 | 4.893B |
| September 01, 2026 | 5.014B |
| August 31, 2026 | 5.364B |
| August 28, 2026 | 5.411B |
| August 27, 2026 | 5.868B |
| August 26, 2026 | 5.761B |
| August 25, 2026 | 5.327B |
| August 24, 2026 | 5.277B |
| August 21, 2026 | 5.286B |
| August 20, 2026 | 5.114B |
| August 19, 2026 | 5.424B |
| August 18, 2026 | 5.433B |
| August 17, 2026 | 5.490B |
| August 14, 2026 | 5.521B |
| August 13, 2026 | 5.358B |
| August 12, 2026 | 5.583B |
| August 11, 2026 | 5.499B |
| August 10, 2026 | 5.439B |
| August 07, 2026 | 5.530B |
| Date | Value |
|---|---|
| August 06, 2026 | 5.486B |
| August 05, 2026 | 5.596B |
| August 04, 2026 | 5.521B |
| August 03, 2026 | 5.352B |
| July 31, 2026 | 5.449B |
| July 30, 2026 | 5.615B |
| July 29, 2026 | 5.314B |
| July 28, 2026 | 5.452B |
| July 27, 2026 | 5.674B |
| July 24, 2026 | 5.749B |
| July 23, 2026 | 5.821B |
| July 22, 2026 | 5.874B |
| July 21, 2026 | 5.833B |
| July 20, 2026 | 5.658B |
| July 17, 2026 | 5.768B |
| July 16, 2026 | 5.721B |
| July 15, 2026 | 6.421B |
| July 14, 2026 | 5.871B |
| July 13, 2026 | 5.371B |
| July 10, 2026 | 5.568B |
| July 09, 2026 | 5.771B |
| July 08, 2026 | 5.674B |
| July 07, 2026 | 5.515B |
| July 06, 2026 | 5.668B |
| July 02, 2026 | 5.549B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 40.91B |
| Tango Therapeutics, Inc. | 3.022B |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.08M |
| Total Expenses (Quarterly) | 44.08M |
| EPS Diluted (Quarterly) | -0.1416 |
| Earnings Yield | -6.01% |
| Normalized Earnings Yield | -3.809 |